Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Edwards Lifesciences (EW) PT Raised to $135 at Oppenheimer
December 9, 2021 6:31 AM ESTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $122.00) while maintaining an Outperform rating following the company's Analyst Day.
The analyst commented, "Edwards hosted its annual analyst day yesterday (12/8). Investors focused on developments in TMTT, especially... More
Edwards Lifesciences (EW) PT Raised to $132 at Stifel Following Analyst Day
December 9, 2021 6:12 AM ESTStifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $129.00) while maintaining a Buy rating following the company's Analyst Day which underscores the key pipeline opportunities driving top-tier growth outlook for next year and beyond.
The analyst commented,... More
Edwards Lifesciences (EW) PT Raised to $140 at Cowen; Named Best 2022 Idea
December 9, 2021 5:49 AM ESTCowen analyst Joshua Jennings raised the price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $125.00) while maintaining an Outperform rating and named the stock a Best Idea for 2022.
The analyst commented, "EW's investor day featured favorable business updates, a reiteration of '21 guidance... More
